About Us  |   Contact Us  |   Register  | Login  |   

Follow HedgeWorld on Twitter HedgeWorld on LinkedIn






HEDGEWORLD NEWS
Search the News
News Archive
HedgeWorld News by Region
United States / Americas
Europe
Asia / Australia
International
HedgeWorld News Sections
Managed Futures & Derivatives
Daily News
Regulatory/Legal
Strategies/Analysis
Technology
Opinion
People
Indexes
Other News Features
Most Popular
Reuters Headlines
Alternative Advantage Daily Newsletter
RSS Service
Sign Up For Email News Alerts
Reprints

Allergan seeks deal with Salix to fend off Valeant: report
By Reuters
Tuesday, August 19, 2014 Email this story  |  News Tracker  |  Reprints  |  Printable Version

IRVINE, Calif. (Reuters)—Botox maker Allergan Inc. has approached Salix Pharmaceuticals Ltd. and at least one other company about a potential takeover in a bid to avert the $53 billion hostile takeover from Valeant Pharmaceuticals International Inc., The Wall Street Journal reported.

Allergan and Salix declined to comment on the matter.

The share price of Salix, which itself is in the process of merging with a unit of Swiss-listed Cosmo Pharmaceuticals, jumped about 10 percent on Tuesday [Aug. 19].

It isn't clear where any talks with Salix stand, but one of the sources said Allergan could strike a takeover deal with the company or another unknown party as early as next month, the Journal said.

Raleigh, North Carolina-based Salix makes products used to prevent or treat gastrointestinal disorders. So far, it has generated sales of $766.4 million this year.

Cosmo said in July it would merge its Irish subsidiary with Salix, another example of overseas deal-making by U.S. companies seeking to lower their tax bill by shifting tax domiciles abroad.

William Ackman's hedge fund, Pershing Square Capital Management, which owns nearly 10 percent of Allergan, worked with Valeant to put together the takeover deal unveiled in April.

By Natalie Grover and Amrutha Penumudi in Bangalore


Send This Story to a Friend | Order Reprints Online
Send Feedback to the Editors | Receive News Alerts by Email
Display Printable Version of This Story

Story Copyright © 1999-2014 Reuters HedgeWorld All rights reserved.






Lipper    Privacy   User Policy  Legal Disclosure Copyright/DMCA  Site Map    FAQ    Glossary  Thomson Reuters for Hedge Funds
All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of HedgeWorld content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. HedgeWorld is a registered trademark of Thomson Reuters.